Hester Biosciences Ltd
NSE:HESTERBIO
Hester Biosciences Ltd
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat and currently employs 584 full-time employees. Its segments include Poultry division and Animal division. The company provides over 40 products across poultry vaccines (live and inactivated), animal vaccines (live and inactivated), health products and diagnostics. Its product range includes vaccines, drugs, feed supplements and disinfectants. The company manufactures over two live vaccines for large animals, including Peste des Petits Ruminants (PPR) Live vaccines and Goat Pox Vaccine. Its offerings include Avian, including Live B1, Live LAS, Live R2B, Live M48, Live FP, Gumboro M1, Gumboro I and Gumboro I+; swine fever vaccines, and animal, including PPR Vaccine-Sungri 96 strain and Brucella abortus (S19) calf Vaccine. The company offers services, such as seromonitoring for poultry farms and mastitis prevention programs for cattle farms.
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat and currently employs 584 full-time employees. Its segments include Poultry division and Animal division. The company provides over 40 products across poultry vaccines (live and inactivated), animal vaccines (live and inactivated), health products and diagnostics. Its product range includes vaccines, drugs, feed supplements and disinfectants. The company manufactures over two live vaccines for large animals, including Peste des Petits Ruminants (PPR) Live vaccines and Goat Pox Vaccine. Its offerings include Avian, including Live B1, Live LAS, Live R2B, Live M48, Live FP, Gumboro M1, Gumboro I and Gumboro I+; swine fever vaccines, and animal, including PPR Vaccine-Sungri 96 strain and Brucella abortus (S19) calf Vaccine. The company offers services, such as seromonitoring for poultry farms and mastitis prevention programs for cattle farms.
Poultry Division Strength: Poultry Healthcare business grew 32% in Q3 and 17% over nine months, driven by better market penetration and demand for core vaccines.
Profit Surge: Standalone Q3 profit after tax rose 140% year-over-year, aided by favorable product mix and cost discipline.
Operational Discipline: Despite a 5% revenue decline over nine months, profits increased 16%, highlighting strong operating controls.
Animal Health Headwinds: Animal Healthcare revenue fell 38% in Q3 due to delays in government immunization programs and seasonal factors, but management maintains these are temporary timing issues.
Capacity Expansion: The new fill/finish facility has doubled drug product capacity; further capitalization of capex is expected soon.
H9N2 Vaccine Milestone: Received manufacturing licenses for the H9N2 Avian Influenza vaccine, strengthening the poultry product portfolio.
Export & Africa Strategy: Africa revenue reached INR 27.5 crores for nine months; company continues to expand its export focus and reduce reliance on tenders.
